Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis

One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the pur...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology 2014-05, Vol.52 (5), p.1429-1434
Main Authors: Noh, John, Rodriguez, Silvia, Lee, Yeuk-Mui, Handali, Sukwan, Gonzalez, Armando E, Gilman, Robert H, Tsang, Victor C W, Garcia, Hector H, Wilkins, Patricia P
Format: Article
Language:English
Subjects:
Animals
Antibodies, Helminth - blood
Antibodies, Helminth - immunology
Antigens, Helminth - blood
Antigens, Helminth - immunology
Glycoproteins - immunology
Humans
Immunoblotting - methods
Neurocysticercosis - blood
Neurocysticercosis - diagnosis
Neurocysticercosis - immunology
Parasitology
Peptides - immunology
Peru
Recombinant Proteins - immunology
Sensitivity and Specificity
Taenia solium - immunology
Taeniasis - blood
Taeniasis - diagnosis
Taeniasis - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.
ISSN:0095-1137
1098-660X
DOI:10.1128/JCM.03260-13